Delivery Order SPE2DB20D3103-SPE2DB23FP6K9
- Not listed
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $5,760.81 firm fixed-price delivery order is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has an ultimate completion date of April 26, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026....
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The Delivery Order, valued at $28,595.22, is for the procurement of DUPIXENT 200 MG/1.14 ML PEN 1.14ML, a pharmaceutical product. The contract has a firm fixed price pricing type and a period of performance through December 28, 2023. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $27,251.28 firm fixed-price delivery order is for 4560894596 DUPIXENT 200 MG/1.14 ML PEN 1.14ML, a pharmaceutical product, with a period of performance through May 11, 2023. There is no set-aside designation for this award. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to supply DUPIXENT 200 MG/1.14 ML PEN 1.14ML. The fixed-price delivery order, valued at $16,523.60, has a period of performance ending on September 19, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $27,100.61 firm fixed-price delivery order is for the supply of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. The contract has an ultimate completion date of May 6, 2024. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order with a Firm Fixed Price of $10,434.52 for the supply of DUPIXENT 300 MG/2 ML PEN 2ML medication. The contract, awarded by the Defense Logistics Agency (DLA), has an ultimate completion date of April 29, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $4,957.05 Firm Fixed Price Delivery Order is for the supply of DUPIXENT 200 MG/1.14 ML PEN 1.14ML, a pharmaceutical product, with a performance period through April 29, 2024. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the...
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $7,480.06 firm fixed price contract is for the supply of DUPIXENT 200 MG/1.14 ML PEN 1.14ML, a specialty pharmaceutical product, with a completion date of December 1, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $17,576.10 delivery order contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has a period of performance through January 26, 2024 and utilizes a firm fixed price pricing structure. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp is a major...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $46,957.78 firm fixed-price delivery order is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product. The contract has an ultimate completion date of February 7, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB23FP6K9Delivery Order
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $18,351.17 firm-fixed-price delivery order covers the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, with a period of performance through September 7, 2023. The contract was awarded on an unrestricted, full and open competition basis, with no set-aside designation. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas. Amerisourcebergen also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.4k | 9/6/23 |